Roche has developed a new class of IL-2 variants (IL-2v) with biased binding properties, some of which are additionally targeted to cell-surface proteins overexpressed in tumors or the surrounding stroma to enhance local tumor retention, such as CEA-IL2v [23] and FAP-IL2v [24], which have shown improved therapeutic efficacy. The gene discussed is IL2; the disease is neoplasm.